Summary Despite the scientific and technical capacity for precision oncology in North America (Canada, the United States, and Mexico), its implementation is deeply uneven across the region. Our narrative synthesis of precision oncology implementation found that delivery consistently fails at four operational steps: bio...
Priya Kumar, A. Salawu, R. Demichelis-Gómez et al.· The Lancet Regional Health -...· 0 citations
PURPOSE
This first-in-human, nonrandomized, multicenter study investigated nelistotug (anti-CD96 monoclonal antibody [mAb]) as monotherapy (Arm A) and in combination with dostarlimab (anti-PD-1 mAb) (Arm B), and dostarlimab plus belrestotug (anti-TIGIT mAb) (Arm F) in patients with recurrent or advanced solid tumors....
L. Siu, Omid Hamid, Reva Schneider et al.· Clinical Cancer Research· 0 citations
OBJECTIVES
To describe metastatic characteristics and outcomes in patients with de novo metastatic (cM1) head and neck squamous cell carcinoma (HNSCC).
METHODS
cM1 HNSCC patients diagnosed between 2001 and 2024 were reviewed. Metastatic characteristics and management patterns were collected, including the timing of l...
A. Rühle, E. Sanz-García, Jie Su et al.· Radiotherapy and Oncology· 0 citations
Head and Neck Head and Neck Squamous Cell Carcinoma (HNSCC) is driven by an immunosuppressive tumor microenvironment (TME). We examined the immune-modulatory role of EphA4 in HNSCC using spatial analysis, multi-compartment RNA-sequencing from Oral Cavity Squamous Cell Carcinoma (OCSCC), and three genetically engineered...
S. Corbo, Khalid N. M. Abdelazeem, D. Nguyen et al.· Cancer immunology research· 0 citations
CD8 T-cell populations showed the strongest methodological concordance, establishing their priority as a robust candidate biomarker for immune activation to be used in further clinical research.
C. Gaspar, Benson Z. Wu, Simone C. Stone et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.